This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Michael J. Fox Foundation Launches New Funding Opportunities For Parkinson's Research





NEW YORK, May 8, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) is today announcing the launch of three new funding programs focused on driving research toward transformative treatments and a cure for Parkinson's disease (PD). Two programs will promote critical work on the promising therapeutic targets LRRK2 and Parkin. A third program allows researchers to propose developing biomarkers of cognitive impairment in PD. The new funding opportunities are open to both academic and industry researchers.

In addition to these new programs, five other programs are currently open and accepting applications. Check out the complete list and apply for funding at https://www.michaeljfox.org/research/apply-for-grant.html.

Brief descriptions of the three launching programs follow. 

LRRK2 Role in Idiopathic Parkinson's Disease 2013

MJFF invites proposals that can establish whether pathological mechanisms linked to LRRK2-associated parkinsonism underlie the more common idiopathic forms of PD. A clear answer to this question would provide additional insight into underlying causes of PD and greatly energize efforts to develop and test LRRK2-targeted therapeutics beyond those populations with established LRRK2 genetic parkinsonism.

Informational Conference Call: May 30, 2013, 12:00 p.m. ETPre-Proposals Due: June 19, 2013, 6:00 p.m. ET

To participate in the call and receive call-in details, please RSVP via email to  conferencecalls@michaeljfox.org.

Parkin Biology & Therapeutic Development 2013



MJFF invites proposals that promote understanding of the biological function and therapeutic potential of Parkin. Mutations in the Parkin gene explain a large proportion of PD cases occurring before the age of 40 and could represent a promising therapeutic agent to alter the course of PD.

Informational Conference Call: June 6, 2013, 12:00 p.m. ETPre-proposals Due: June 19, 2013, 6:00 p.m. ET

To participate in the call and receive call-in details, please RSVP via email to  conferencecalls@michaeljfox.org.

Cognition Biomarkers RFA 2013

MJFF invites proposals aimed at developing biomarkers of cognitive impairment in PD useful for future clinical trials. Particular emphasis will be on projects designed to develop biomarkers that identify transition between normal and impaired cognition, as well as between cognitive impairment and dementia.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,446.36 -232.34 -1.31%
S&P 500 2,035.77 -21.32 -1.04%
NASDAQ 4,704.7120 -67.0510 -1.41%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs